Cargando…
X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL
Acute lymphoblastic leukemia (ALL) represents the most frequent malignancy in children, and relapse/refractory (r/r) disease is difficult to treat, both in children and adults. In search for novel treatment options against r/r ALL, we studied inhibitor of apoptosis proteins (IAP) and Smac mimetics (...
Autores principales: | Carlet, Michela, Schmelz, Karin, Vergalli, Jenny, Herold, Tobias, Senft, Daniela, Jurinovic, Vindi, Hoffmann, Thomas, Proba, Jutta, Weichert, Nina, Junghanß, Christian, Roth, Mareike, Eschenburg, Georg, Barz, Malwine, Henze, Günter, Eckert, Cornelia, Eggert, Angelika, Zuber, Johannes, Hundsdoerfer, Patrick, Jeremias, Irmela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832863/ https://www.ncbi.nlm.nih.gov/pubmed/36416169 http://dx.doi.org/10.15252/emmm.202114557 |
Ejemplares similares
-
Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma
por: Arnhold, Viktor, et al.
Publicado: (2017) -
In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
por: Carlet, Michela, et al.
Publicado: (2021) -
Adverse stem cell clones within a single patient’s tumor predict clinical outcome in AML patients
por: Zeller, Christina, et al.
Publicado: (2022) -
Priority-Lasso: a simple hierarchical approach to the prediction of clinical outcome using multi-omics data
por: Klau, Simon, et al.
Publicado: (2018) -
In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance
por: Wirth, Anna-Katharina, et al.
Publicado: (2022)